{
  "image_filename": "table_p2_det_1_017.png",
  "image_path": "FlublokPI/extracted/figures/table_p2_det_1_017.png",
  "image_type": "Table",
  "page_number": 2,
  "block_id": "det_1_017",
  "claim_id": "claim_000",
  "claim": "Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains.",
  "supports_claim": false,
  "explanation": "A table comparing solicited local and systemic adverse event rates (%) after vaccination with Flublok (N=1078) versus an egg-based inactivated influenza vaccine (IIV3, N=1081), listing percentages of any, moderate, and severe pain, redness, firmness/swelling, fatigue, headache, muscle pain, joint pain, shivers/chills, nausea, and fever. does not support the claim: the table presents safety and reactogenicity data, not information on antigenic match with WHO- or FDA-selected flu strains.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": false,
    "image_description": "A table comparing solicited local and systemic adverse event rates (%) after vaccination with Flublok (N=1078) versus an egg-based inactivated influenza vaccine (IIV3, N=1081), listing percentages of any, moderate, and severe pain, redness, firmness/swelling, fatigue, headache, muscle pain, joint pain, shivers/chills, nausea, and fever.",
    "evidence_found": null,
    "reasoning": "does not support the claim: the table presents safety and reactogenicity data, not information on antigenic match with WHO- or FDA-selected flu strains.",
    "confidence_notes": null
  }
}